ArticleAntibiotics (Basel, Switzerland)2022
Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 9 citations in OpenAlex.
- Long-term trends in ceftolozane-tazobactam susceptibility among gram-negative pathogens in the United States: a nine-year SMART analysis (2016-2024).JAC-antimicrobial resistance · 2026Article
- Genetic Analysis of Virulence and β-Lactamase Determinants Related to β-Lactamase Inhibitors inAntibiotics (Basel, Switzerland) · 2025Article
- Trends inAntibiotics (Basel, Switzerland) · 2025Article
- Mutational Analysis of Colistin-ResistantPathogens (Basel, Switzerland) · 2025Article
- Article
- Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.JAC-antimicrobial resistance · 2024Article
- Satisfactory In Vitro Activity of Ceftolozane-Tazobactam against Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2023Article
- Ceftolozane/Tazobactam In-Vitro Activity against Clinical Isolates from Complicated Intra-Abdominal Infection Patients in Three Indonesian Referral Hospitals.Antibiotics (Basel, Switzerland) · 2022Article
- Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 6 countries.
Funding
Abstract
backgroundCeftolozane/tazobactam (C/T) is a combination of an antipseudomonal oxyiminoaminothiazolyl cephalosporin with potent in vitro activity against
methodsa total of 2760 clinical isolates (508
resultsaccording to the CLSI breakpoints, 68.1% (346/508) of
conclusionsthese results show that C/T is an active β-lactam agent against clinical isolates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.